. 2018 Sep 20;5(1):91–96. doi: 10.1001/jamaoncol.2018.3732

Table 2. Crude Event Incidence for Metastases, Prostate Cancer-Specific Mortality, and All-Cause Mortality.

Trial	Arm	GG 4				GG 5
		Total	No.			Total	No.
		Total	DM	PCSM	ACM	Total	DM	PCM	ACM
RTOG
Pilepich et al, 2005⁴	RT alone	61	50	23	49	47	42	25	41
Pilepich et al, 2005⁴	Lifelong ADT	59	43	17	38	49	39	12	38
Pilepich et al, 2001⁵	RT Alone	33	29	16	27	36	31	25	30
Pilepich et al, 2001⁵	STADT	29	25	12	25	30	25	16	25
Horwitz et al, 2008⁶	STADT	93	78	36	79	78	67	27	64
Horwitz et al, 2008⁶	LTADT	92	79	20	79	74	60	20	60
EORTC
Bolla et al, 1997⁷	RT alone	17	15	8	13	7	6	4	4
Bolla et al, 1997⁷	LTADT	13	6	2	5	6	2	0	2
Bolla et al, 2009⁸	STADT	56	22	3	18	34	18	9	15
Bolla et al, 2009⁸	LTADT	75	21	9	21	21	7	3	6
Bolla et al, 2016⁹	RT Alone	29	10	2	10	8	4	3	4
Bolla et al, 2016⁹	STADT	36	7	2	6	9	3	2	2
Total		593	385	150	370	399	304	146	291
Event rate, %			64.9	25.3	62.4		76.2	36.6	72.9

Abbreviations: ACM, number of all-cause mortality events; ADT, androgen deprivation therapy; DM, number of distant metastases; GS, Gleason score; LTADT, long-term ADT; PCSM, number of prostate cancer-specific mortality events; RT, radiation therapy; STADT, short-term ADT.